Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer

Shirley Xue Jiang1,2 | Ryan N. Walton3 | Katrina Hueniken1 | Justine Baek1,2 | Alexandra McCartney1 | Catherine Labbé4 | Elliot Smith1,2 | Sze Wah Samuel Chan1,2 | RuiQi Chen1,2 | Catherine Brown1 | Devalben Patel1 | Mindy Liang1 | Lawson Eng1,2 | Adrian Sacher1,2 | Penelope Bradbury1,2 | Natasha B. Leigh1,2 | Frances A. Shepherd1,2 | Wei Xu5 | Geoffrey Liu1,2,5,6 | Manjusha Hurry3 | Grainne M. O’Kane1,2

Abstract

Background: As the treatment landscape in patients with non-small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFRm) continues to evolve, real-world health utility scores (HUS) become increasingly important for economic analyses.

Methods: In an observational cohort study, questionnaires were completed in EGFRm NSCLC outpatients, to include demographics, EQ-5D-based HUS and patient-reported toxicity and symptoms. Clinical and radiologic characteristics together with outcomes were extracted from chart review. The impact of health states, treatment type, toxicities, and clinical variables on HUS were evaluated.

Results: Between 2014 and 2018, a total of 260 patients completed 994 encounters. Across treatment groups, patients with disease progression had lower HUS compared to controlled disease (0.771 vs 0.803; \( P = .01 \)). Patients predominantly received gefitinib as the first-line EGFR tyrosine kinase inhibitor (TKI) (\( n = 157 \), mean-HUS = 0.798), whereas osimertinib (\( n = 62 \), mean-HUS = 0.806) and chemotherapy (\( n = 38 \), mean-HUS = 0.721) were more likely used in subsequent treatment lines. In longitudinal analysis, TKIs retained high HUS (>0.78) compared to chemotherapy (HUS < 0.74). There were no differences between the frequency or severity of toxicity scores in patients receiving gefitinib compared to osimertinib; however, TKI therapy resulted in fewer toxicities than chemotherapy (\( P < .05 \)), with the exception of worse diarrhea and skin rash (\( P < .001 \)). Severity in toxicities inversely correlated with HUS (\( P < .001 \)). Clinico-demographic factors significantly affecting HUS included age, Eastern Cooperative Oncology Group Performance Score (ECOG PS), disease state, treatment group, and metastatic burden.
While TKIs are associated with fewer adverse effects compared to chemotherapy, the longer time on therapy may result in chronicity and decreases in health utility. When the health states of a general advanced NSCLC population were examined, commonly observed symptoms such as cough, dyspnea, and pain corresponded with a mean utility loss of 0.069. Within an EGFRm-specific population, poor appetite and fatigue have been associated with lower HUS. Furthermore, recent studies have demonstrated that treatment-related adverse effects correlate with different quality of life across TKI agents; however, these data are limited to gefitinib, erlotinib, and afatinib. While there have been new advances in EGFRm treatments and it has been shown that different treatments have implications on HUS, there remains limited data on the impact of treatment and toxicities in an EGFRm population.

Health utility scores are commonly generated by EQ-5D, a standardized measure that can be applied in various health and treatment states. The EQ-5D instrument has been validated in a general population as a generic preference-weight measure. In contrast, EGFRm-NSCLC populations are enriched for never-smokers, females, and Asians, differing substantially from the composition of the general, healthy North American population. Even within lung cancer patients, EGFRm patients significantly depart from the typical heavy smoking stereotype. Describing real-world HUS in EGFRm patients under various health states while evaluating the impact of clinico-demographic factors and toxicities on HUS is necessary to generate data that can be used confidently in cost-effectiveness analyses of this subset of NSCLC patients.

2 | MATERIALS AND METHODS

2.1 | Patients

This cohort study was approved by the University Health Network Institutional Research Ethics Board (Toronto, Canada). Participants were outpatients at Princess Margaret Cancer Centre who had advanced, histologically confirmed EGFRm-NSCLC from November 2014 to July 2018.
Participants were all able to provide informed consent and could enroll at any point during their disease course. Longitudinal data were obtained through follow-up surveys collected at regular outpatient visits scheduled by the physician.

2.2 | Questionnaires

The baseline questionnaire included multiple components. A demographic questionnaire collected data surrounding age, sex, ethnicity, and social factors. An EQ-5D questionnaire was comprised of five dimensions (mobility, self-care, usual activity, pain or discomfort, anxiety, or depression), whereby the patient would evaluate their health state on a scale of problem levels ranging from “no problems” to “extreme problems” for each dimension. A single digit score is generated for each dimension and all five dimension scores can be combined using a predetermined formula for a final number between 0 and 1 describing the patient’s health state. The visual analogue scale allows patients to self-rate their health from “the worst healthy you can imagine” (0) to “the best health you can imagine” (100). The baseline questionnaire also evaluated treatment-related symptoms using a questionnaire based on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). In addition to the most relevant PRO-CTCAE items to EGFR-TKIs as identified by expert review (such as diarrhea, fatigue, nausea/vomiting), we included a specific skin toxicity section for inclusion of specific areas affected by and details of non-acneform rashes. Frequency and severity of toxicities were described using a scoring system similar to PRO-CTCAE reporting for each treatment group, whereby a numerical score was assigned to represent the magnitude of severity and frequency of the toxicity item (Table S1). In this scoring, 1 represents absence of any toxicity and 5 represents the most severe or frequent toxicity; with the exception of hair loss and visual disorders, which utilized scores ranging from 1 to 3; and skin rash, which utilized a score between 1 and 4. Follow-up surveys included the EQ-5D questionnaire and the toxicity questions. Additional patient-reported outcome measures for all subjects were extracted from the Edmonton Symptom Assessment System-Distress Assessment and Response Tool (ESAS-DART),34 which is a validated electronic self-assessment symptom screening tool routinely administered to cancer patients at Princess Margaret Cancer Centre at all clinic visits. ESAS-DART provides a score on an 11-point scale from 0 (no symptoms) to 10 (most severe symptom) for 10 key symptoms: pain, tiredness, drowsiness, nausea, appetite, shortness of breath, depression, anxiety, well-being, and functional status.

2.3 | Chart abstraction and variable classification

Clinical data were extracted from medical records, including diagnostic tests, diagnosis date, and stage at diagnosis. Extracted treatment information included all surgical, radiation, and systemic treatments. Regular imaging at Princess Margaret Cancer Centre documented whether patients had radiologic evidence of treatment response, stability, or progression.

Health states were classified into stable or progressive disease. Stable disease was defined by not having any recorded evidence of disease progression radiologically, pathologically or clinically. Progressive disease was defined by reported radiologic, pathologic, or clinical progression documented on the patient’s medical record. Progressive disease was further subdivided into patients demonstrating disease progression while being maintained on the same TKI (ie treatment beyond progression), or demonstrating disease progression where the current TKI was stopped or switched at progression (ie no treatment beyond progression). Toxicity data were categorized as mild, moderate, or severe based on the PRO-CTCAE data, as classified in Table S1.

2.4 | Statistical analysis

Descriptive summary statistics are reported for individual patients, stratified by systemic treatment type (referred to as “treatment group”). Pairwise comparisons evaluated associations between various treatment group definitions and HUS, using t tests. Trends in HUS over time since treatment initiation were plotted using locally weighted polynomial least squares regression (LOESS), stratified by treatment group.

Differences between treatment groups for each toxicity were explored using ANOVA (mean severity) and Kruskal-Wallis tests (proportion of patients reporting moderate to severe toxicity). Pairwise comparisons were then conducted to further explore significant associations between individual toxicities and treatment group and a Bonferroni correction was used to account for multiple comparisons. Boxplots were created to describe associations between each toxicity/ESAS symptom and HUS. Spearman correlational coefficients were generated to describe associations between individual toxicities/symptoms and HUS. Boxplots were also used to visualize trends in HUS when grouped by most severe reported toxicity score or ESAS symptom per clinic visit, stratified by treatment group.

This study collected data at each patient’s clinic visit (referred to throughout this paper as “encounters”); therefore, one patient could contribute multiple HUS at different time points and across varying lines of treatment. To account for
multiple observations per patient in univariable and multivariable analyses, a single mean HUS was calculated per patient within each “health state,” defined as all encounters per patient on a single treatment, within a single disease status (stable or progressing on treatment). For example, patient who contributed HUS both before and after progressing on a single treatment would contribute two “health states” to the analysis on that given treatment: one mean HUS of all scores generated in stable disease, and a second for all scores after disease progression occurred on that treatment.

To examine whether EQ-5D-generated HUS reflected patient’s health state in EGFRm-NSCLC patients, ANOVA was conducted to evaluate unadjusted associations between HUS by health state and key clinical factors. Associations between treatment group and HUS per health state were adjusted for potential confounders using multivariable linear regression. A preliminary regression model was fit using clinic-demographic variables significantly associated with HUS, excluding treatment group, followed by backwards selection. Finally, treatment group was added into the result.

Statistical significance was defined as $P < .05$, with the exception of pairwise comparisons for which the Bonferroni adjustment was applied and statistical significance was $P < .00125$. All analyses were conducted using R, version 3.4.3.

3 | RESULTS

3.1 | Baseline characteristics

Our study included 260 EGFRm-NSCLC outpatients, who provided HUS in 994 clinical encounters; after controlling for each individual patient providing the same health state over multiple visits, we defined 488 individual health states as stable or progressing. The median number of encounters completed by each participant was 3 (range 1-15); participation rate was 87% of all patients approached. Baseline characteristics and treatment received at first encounter for each patient at study entry are reported in Table 1. Throughout the study, 157 patients received gefitinib (149 in first line, 8 subsequent line), 62 received osimertinib (3 first line, 59 subsequent line), 59 received another TKI (19 first line, 40 subsequent line), and 38 were treated with chemotherapy (4 in first line, 34 in subsequent line). Eighty-three patients contributed HUS when not on treatment and 5 contributed HUS on immunotherapy (n = 4) or other treatment (n = 1) throughout the study duration, wherein 1 patient contributed encounters to both no treatment and other treatment.

Significant differences in demographic and clinical characteristics between treatment groups were found. Patients undergoing gefitinib treatment were older (mean 65.8 years) while patients receiving osimertinib (mean 59.0 years) and chemotherapy (mean 57.2 years) were younger ($P = .03$). Line of therapy was significantly different between treatment groups as gefitinib was typically used in the first-line setting; osimertinib, chemotherapy, and other TKIs were generally given at failure of gefitinib ($P < .001$). More metastatic sites were associated with chemotherapy (mean 2.89) when compared to gefitinib (mean 2.05) ($P = .01$) and patients treated with chemotherapy also were more likely to have acquired liver metastasis ($P = .01$). In the osimertinib treatment group, significantly more patients had advanced stage disease (defined as stage IV) at time of first diagnosis (92.9%), compared to patients treated with gefitinib, who were more likely to present at an earlier stage and later develop metastatic disease (59.7% diagnosed at stage IV, 40.3% early-stage; $P = .02$).

3.2 | Disease state and HUS

Mean HUS of all encounters according to disease states and treatment group are shown in Table 2. As expected, across all treatment groups, stable disease (295 individual health states) was associated with higher mean HUS compared to disease progression (193 individual health states) (0.803 vs 0.771; $P = .05$). Gefitinib, osimertinib, and chemotherapy also had consistently numerically higher mean HUS during disease stability, when compared with disease progression. In an exploratory analysis of HUS in patients treated beyond progression, no significant differences in HUS were found between health states of patients who continued their treatment beyond disease progression (n = 58) compared to health states when treatment was stopped or switched (n = 58). The clinical strategy of continuing a TKI beyond progression in selected patients was thus not associated with lower HUS, when compared to stopping the current treatment at progression (0.775 vs 0.739, respectively; $P = .26$).

3.3 | Treatment and HUS

Considering only patients with stable disease in Table 2, all treatment groups were compared with gefitinib, as it was the most commonly used treatment. Comparatively, osimertinib was associated with similar mean HUS (mean HUS of 0.810 gefitinib vs 0.815 osimertinib; $P = .78$). Those treated with chemotherapy had lower mean HUS (mean HUS of 0.756; $P = .04$). Finally, other TKI treatment (primarily, afatinib, and erlotinib) had a mean HUS in between chemotherapy and gefitinib/osimertinib (mean HUS of 0.795). To account for different treatment lines, a univariable analysis was conducted between second-line treatment groups that also demonstrated similar mean HUS...
between osimertinib, gefitinib, and other TKIs, which were superior to chemotherapy.

The LOESS regression curve in Figure 1 represents HUS in patients with stable disease who were treated with gefitinib, osimertinib, other TKIs, and chemotherapy over time, since their treatment was initiated. After excluding the first few months of therapy, which may represent time to stabilization of disease, disease symptoms, initial toxicity symptoms, and HRQoL, there was consistency in the longitudinal data; TKI treatments were similar, retaining durable HUS > 0.75 with osimertinib and gefitinib retaining HUS > 0.80 up to approximately 1 year on treatment. Chemotherapy was consistently associated with the lowest HUS, substantially lower than the cluster formed by the TKI therapies; as the majority of chemotherapy patients progressed within a few months of therapy, longitudinal data beyond a few months was very limited.

### 3.4 Clinical variables and HUS

The role of clinico-demographic factors affecting HUS is outlined in Table 3. In univariable analysis, higher mean HUS was associated with both lower ECOG performance status (ECOG PS) at the time of stage IV diagnosis ($P < .001$), and being in a stable disease state ($P = .01$).

---

**TABLE 1** Baseline patient characteristics by treatment at first encounter

| Characteristic: N (%) | Gefitinib | Osimertinib | Other TKI | Chemo-therapy | None/othera | P-value |
|-----------------------|-----------|-------------|-----------|---------------|-------------|---------|
| Number of patients on treatment at first encounter (study entry) | 129 | 14 | 33 | 18 | 66 |  |
| Age at diagnosis of stage IV disease: mean [SD] | 66[13] | 59 [11]b | 62 [13] | 57 [11]b | 64 [14] | .03 |
| Stage IV at diagnosis: N (%) | 77 (60) | 13 (93)b | 18 (56) | 15 (83) | 36 (55) | .02 |
| Ethnicity |  |
| Asian | 80 (62) | 6 (43) | 12 (38)b | 6 (33)b | 36 (55) | .03 |
| Other | 13 (10) | 3 (21) | 9 (28) | 2 (11) | 8 (12) |  |
| Smoking status at stage IV diagnosis |  |
| Ever smoker | 42 (33) | 2 (14) | 8 (25) | 8 (47) | 20 (31) | .36 |
| Never smoker | 87 (67) | 12 (86) | 24 (75) | 9 (53) | 45 (69) |  |
| ECOG performance status at stage IV diagnosis |  |
| 0 | 43 (33) | 4 (29) | 13 (39) | 6 (33) | 18 (27) | .65 |
| 1 | 75 (58) | 10 (71) | 20 (61) | 12 (67) | 44 (67) |  |
| 2+ | 11 (9) | 0 (0) | 0 (0) | 0 (0) | 4 (6) |  |
| Lines of treatment: first line, N (%) | 123 (95) | 0 (0)b | 14 (42)b | 2 (11)b | 56 (85)b | <.001 |
| Number of metastatic sites involved: mean [SD] | 2.1 [1.2] | 2.4 [1.0] | 2.0 [1.1] | 2.9 [1.2]b | 1.9 [1.1] | .02 |
| Bone metastasis: N (%) | 62 (48) | 10 (71) | 15 (46) | 12 (67) | 25 (38) | .08 |
| Brain metastasis: N (%) | 50 (39) | 8 (57) | 6 (18)b | 11 (61) | 23 (35) | .02 |
| Pleural effusion: N (%) | 49 (38) | 4 (29) | 15 (46) | 8 (44) | 23 (35) | .76 |
| Liver metastasis: N (%) | 17 (13) | 4 (29) | 5 (15) | 8 (44)b | 8 (12) | .01 |
| Nodal metastasis: N (%) | 75 (58) | 7 (50) | 23 (70) | 13 (72) | 42 (64) | .52 |
| Adrenal metastasis: N (%) | 11 (9) | 1 (7) | 3 (9) | 0 (0) | 7 (11) | .77 |
| Total number of patients on treatment at any encounter/total encounters in studya | 157/419 | 62/195 | 59/169 | 38/87 | 87/124 |  |

aOf 66 total patients, 65 were not on treatment and one was on immunotherapy.

b$P < .05$ on pairwise comparison with reference of gefitinib, using Fisher’s exact (categorical variables) or $t$ tests (continuous variables).

*At first encounter.

dThe total number of patients on each treatment sums to more than n = 260 because some patients contributed data to the study on multiple treatments.

Significant $P$-values (< 0.05) were bolded.
Higher mean HUS was also associated with the absence of bone ($P = .004$), liver ($P = .02$) and pleural ($P = .04$) metastases and a lower number of metastatic sites ($P = .02$). Notably, mean HUS did not decrease with brain metastasis. Mean HUS were not significantly associated with line of treatment ($P = .56$) but HUS did vary by current systemic treatment ($P = .01$).

In multivariable analysis, lower HUS was significantly associated with more advanced age at stage IV diagnosis ($P = .007$), a higher ECOG score at first diagnosis ($P < .01$), having disease progression at the time of assessment ($P = .006$), and having an increasing number of metastatic sites ($P = .03$; see Table 3). Bone, liver, and pleural metastases were not found to contribute to the regression model, thus no metastatic sites were included in the final MVA. After adjusting for clinically relevant variables and using gefitinib as the reference, HUS was similar across all different types of TKI therapy while HUS was inferior in patients who were treated with chemotherapy ($P = .02$) or not on treatment ($P = .01$).

### 3.5 Frequency and severity of treatment-related toxicities

Table 4 summarizes the frequency and severity of 10 common toxicities (scored according to Supplementary Table 1) reported at any encounter, separated by treatment group. After Bonferroni adjustment, significance was defined as $P < .00125$.

Compared to gefitinib, osimertinib had lower mean severity of skin rash ($P = .001$); all other treatment-related toxicities were similar between osimertinib and gefitinib treatment groups. Patients who were untreated ($n = 83$) or on another treatment ($n = 5$), had significantly less severe diarrhea and skin rash compared to gefitinib, which are established side effects of TKIs. When comparing gefitinib and chemotherapy, the first line TKI was associated with less severe decreased appetite, nausea, vomiting, and fatigue; however, chemotherapy had superior profile for skin rash and diarrhea ($P < .0013$). A similar trend was seen when examining the frequency of all toxicities. There was no significant difference in toxicity frequency between gefitinib, osimertinib, and other TKIs ($P > .0012$); however, chemotherapy was associated with a higher frequency of reported constipation, decreased appetite, nausea, vomiting, and fatigue ($P < .0012$).

Severity of treatment toxicity from TKIs, including gefitinib, and osimertinib, were compared to chemotherapy in Table S2. As expected, chemotherapy was associated with significantly or numerically higher severity of constipation, decreased appetite, nausea, vomiting, fatigue, neuropathy, and hair loss ($P < .05$). However, chemotherapy was again associated with lower severity of diarrhea ($P = .001$) and skin rash ($P = .008$), which was more common with TKI use.
3.6 | Toxicities and HUS

The box plots in Figure 2 illustrate the relationship between the most severe reported toxicity among all 10 toxicities and their corresponding HUS, according to treatment group. There was an overall trend where increasing severity of the most-severe toxicity corresponded to poorer HUS. When examining HUS by treatment group, chemotherapy was consistently associated with the lowest median HUS, when compared to all of the TKI treatment groups, across each level of the most severe reported toxicity.

Figure 3A demonstrates the relationship between HUS and severity of individual symptoms and toxicities, across all treatment groups. Increasing toxicity severity scores correlated with decreasing HUS for each of the individual symptoms ($\rho = -0.16$ to $-0.56$), except for diarrhea ($\rho = 0.003$) and skin rash ($\rho = -0.03$). To further explore the relationships between HUS and toxicities specifically associated with TKI treatment (ie diarrhea, skin rash), treatment groups were separated into common TKIs (combining gefitinib and osimertinib) and chemotherapy, using Spearman correlation to describe the trends in HUS among patients on each treatment in Figure S1. This figure suggests that all toxicities except skin rash in TKI-treated patients had some degree of association with HUS.

The ESAS tool was completed by 160 (62%) of all outpatients at any clinical encounter during their treatment. Figure 3B shows that higher overall severity score collected by the ESAS tool was associated with lower HUS ($\rho = -0.39$ to $-0.62$; all $P < .001$), with the rho values trending higher than those seen with the reported toxicity scores.

4 | DISCUSSION

In this real-world study of patients with EGFRm NSCLC, HUS and patient-reported toxicities were similar across various TKIs, which were superior to patients on chemotherapy or no treatment. In longitudinal analysis, chemotherapy was associated with the lowest HUS, while both osimertinib and gefitinib retained high HUS over time with mean HUS values above 0.80, as long as disease remained non-progressing. It is important to note that patients treated with chemotherapy may intrinsically have a lower HUS as these patients may be further in their disease course. However, despite also being used in a subsequent line-setting, osimertinib was associated with high HUS and in this real world setting, a mean HUS of 0.815 for stable disease and 0.786 at progression, are comparable to the AURA2 clinical trial data that reported mean HUS of 0.812 and 0.751, respectively.35 For all TKIs, progression was associated with a mean fall in HUS of approximately $\leq 0.03$, less than a previously reported minimally clinically important difference in EQ-5D utility of 0.06-0.08.36 There are three possible explanations for this small drop in mean HUS. First, some patients may have oligoprogression, whereby tumor heterogeneity affords many patients continued benefit from the current TKI treatment despite progression of some clones.37 Second, the high
TABLE 3  Clinico-demographic factors affecting HUS from all encounters

| Covariate               | Category       | N = 488a | Univariable analysis | Multivariable analysisb |
|-------------------------|----------------|----------|----------------------|-------------------------|
|                         |                |          | Mean HUS by health   | Change in HUS, regression β (95% CI) | P-value  |
|                         |                |          | state (95% CI)       | P-value                 | P-value  |
| Age at diagnosis of stage IVc | 65+           | 304      | 0.79 (0.77-0.81)     | -0.002 (−0.003, 0)     | .007     |
|                         | Under 65       | 184      | 0.77 (0.74-0.79)     |                         |          |
| Sex                     | Male           | 162      | 0.79 (0.76-0.81)     |                         | .63      |
|                         | Female         | 326      | 0.78 (0.76-0.79)     |                         |          |
| ECOG PS at stage IV     | 0              | 168      | 0.83 (0.80-0.86)     | Reference              |          |
|                         | 1              | 297      | 0.76 (0.74-0.78)     | -0.051 (−0.08, −0.02)  | .001     |
|                         | 2+             | 23       | 0.67 (0.62-0.72)     | -0.13 (−0.20, −0.06)   | <.001    |
| Disease state           | Stable         | 295      | 0.80 (0.78-0.81)     | Reference              |          |
|                         | Progressing    | 193      | 0.76 (0.73-0.78)     | -0.042 (−0.07, −0.01)  | .006     |
| Line of treatment       | 1              | 278      | 0.79 (0.77-0.81)     |                         | .56      |
|                         | 2              | 118      | 0.77 (0.74-0.80)     |                         |          |
|                         | 3+             | 92       | 0.77 (0.74-0.81)     |                         |          |
| Treatment at encounterb | Gefitinib      | 209      | 0.79 (0.77-0.81)     | Reference              |          |
|                         | Osimertinib    | 81       | 0.80 (0.77-0.84)     | 0.006 (−0.04, 0.05)    | .78      |
|                         | Chemotherapy   | 46       | 0.73 (0.68-0.77)     | -0.062 (−0.12, −0.01)  | .02      |
|                         | Other TKI      | 69       | 0.80 (0.77-0.83)     | 0.0006 (−0.04, 0.04)   | .98      |
|                         | None/other     | 83       | 0.74 (0.70-0.78)     | -0.048 (−0.09, −0.01)  | .01      |
| Number of metastatic sitesc | 0             | 24       | 0.79 (0.71-0.88)     | -0.014 (−0.03, −0.002) | .03      |
|                         | 1              | 116      | 0.81 (0.79-0.84)     |                         |          |
|                         | 2              | 160      | 0.79 (0.77-0.82)     |                         |          |
|                         | 3              | 104      | 0.76 (0.72-0.79)     |                         |          |
|                         | 4              | 65       | 0.74 (0.69-0.78)     |                         |          |
|                         | 5+             | 19       | 0.73 (0.65-0.80)     |                         |          |
| Brain metastasis        | Yes            | 218      | 0.78 (0.76-0.80)     |                         | .73      |
|                         | No             | 270      | 0.78 (0.76-0.80)     |                         |          |
| Bone metastasis         | Yes            | 245      | 0.76 (0.74-0.78)     |                         | .004     |
|                         | No             | 243      | 0.80 (0.78-0.82)     |                         |          |
| Liver metastasis        | Yes            | 89       | 0.74 (0.70-0.78)     |                         | .02      |
|                         | No             | 399      | 0.79 (0.77-0.80)     |                         |          |
| Pleural effusion or metastasis | Yes     | 200      | 0.76 (0.74-0.79)     |                         | .04      |
|                         | No             | 288      | 0.79 (0.77-0.81)     |                         |          |
| Nodal metastasis        | Yes            | 307      | 0.77 (0.75-0.79)     |                         | .15      |
|                         | No             | 181      | 0.79 (0.77-0.82)     |                         |          |

aNumber of health states per line of therapy per person to account for multiple observations per patient.

bThe multivariable model presented was created by entering all variables significant at P = .05, with the exception of treatment at encounter. After backwards selection, the resultant model was created that then forced treatment at encounter back into the multivariable model; it is this final multivariable model that is being presented.

cThis variable was entered into the multivariable analysis as continuous. It has been reported in categories for the univariable analysis to show distributions of HUS. Significant P-values (< 0.05) were bolded.

HUS derived from prior disease stability during TKI therapy may provide a reserve to allow patients to better tolerate disease progression. Third, EGFRm disease progression may include a subset that tends to be slower, leading to milder disease progression symptoms than other forms of NSCLC. It is likely that all three explanations contributed to this relatively small fall in HUS at the time of disease progression. Nonetheless, these EGFRm-specific explanations argue that this subpopulation of patients needs to be treated and analyzed separately from other forms of lung cancer.
| TABLE 4  | Toxicities by treatment |
|----------|-------------------------|
|          | Gefitinib               | Osimertinib          | Other TKI          | Chemotherapy        | None/other          |          |
|          | Any (%), Grade 3-5 (%), Mean grade [SE] | Any (%), Grade 3-5 (%), Mean grade [SE] | Any (%), Grade 3-5 (%), Mean grade [SE] | Any (%), Grade 3-5 (%), Mean grade [SE] |          |
| Number of encounters | N = 243 | N = 127 | N = 97 | N = 52 | N = 64 |          |
| Number of patients | N = 113 | N = 56 | N = 44 | N = 27 | N = 45 |          |
| Diarrhea | 72 40 2.27 [0.07] | 71 40 2.23 [0.09] | 78 47 2.46 [0.11] | 50 23 1.75 [0.12]^a | 50 22 1.77 [0.12]^b | <.001 <.001 |
| Constipation | 54 26 1.88 [0.07] | 42 12 1.54 [0.10] | 44 23 1.82 [0.14] | 82b 25 2.25 [0.16] | 63 45 2.26 [0.16] | .002 .002 |
| Decreased appetite | 46 19 1.71 [0.06] | 58 29 1.99 [0.09] | 61 29 2.05 [0.11] | 73b 46 2.40 [0.16]^a | 64 30 2.09 [0.14] | <.001 <.001 |
| Nausea | 34 12 1.49 [0.05] | 30 10 1.45 [0.07] | 44 9 1.58 [0.09] | 81b 44 2.40 [0.14]^a | 42 17 1.72 [0.13] | <.001 <.001 |
| Vomiting | 19 4 1.23 [0.03] | 25 5 1.30 [0.05] | 22 5 1.28 [0.06] | 54b 35 1.94 [0.14]^a | 33 13 1.48 [0.10] | <.001 <.001 |
| Fatigue | 78 37 2.24 [0.06] | 80 37 2.30 [0.09] | 89 51 2.61 [0.10] | 98b 73 2.96 [0.11]^a | 89 44 2.58 [0.13] | <.001 <.001 |
| Neuropathy | 33 11 1.45 [0.06] | 46 13 1.59 [0.11] | 55 22 1.82 [0.12] | 54 31 1.92 [0.16] | 40 23 1.67 [0.14] | .02 .01 |
| Skin rash | 75 46 2.26 [0.08] | 45 26 1.71 [0.14]^a | 72 40 2.19 [0.13] | 47 22 1.69 [0.14]^a | 30b 19 1.51 [0.13]^b | <.001 <.001 |
| Visual disorders | 42 11 1.53 [0.04] | 64 19 1.83 [0.07] | 48 14 1.62 [0.08] | 53 16 1.69 [0.10] | 42 8 1.50 [0.08] | .001 .002 |
| Hair loss | 37 15 1.52 [0.06] | 21 8 1.29 [0.10] | 36 17 1.53 [0.11] | 69 28 1.97 [0.13] | 30 9 1.40 [0.10] | <.001 <.001 |

^a P < .00125 on pairwise comparison with gefitinib as reference, using t tests to compare mean scores.

^b P < .00125 on pairwise comparison with gefitinib as reference, using Mann-Whitney U tests to compare raw scores.

^c P-values computed across all treatment groups using Kruskal-Wallis method.

^d P-values computed across all treatment groups using ANOVA (mean severity).
We found that our real-world patient-reported symptoms (ESAS) and toxicity grading (similar to PRO-CTCAE) generated data closely resembling reports from clinical trials. From our toxicity scores, we found that higher frequency and severity of diarrhea and skin rash were the only toxicities worsened with TKI treatment compared to chemotherapy or no treatment. This expands upon a meta-analysis of RCTs examining gefitinib, erlotinib, afatinib, and chemotherapy that found rash and diarrhea to be the most frequent TKI-specific toxicities. In contrast, patients treated with chemotherapy were more likely to develop nausea, vomiting, fatigue and loss of appetite, which is consistent with chemotherapy treatment in wild-type NSCLC patients. The cumulatively higher number and severity of toxicities associated with chemotherapy treatment also explains why there was a greater negative impact of chemotherapy on HUS than with TKI therapy, when analysis were stratified by the single worst symptom/toxicity (Figure 2). Finally, regarding the new agent osimertinib, the FLAURA study reported less grade 3 toxicities of osimertinib compared to standard TKI therapy (34% vs 45%) when used in a first-line setting. In our real-world study, osimertinib was used primarily in a second-line setting, suggesting greater burden of disease in patients given progression on first-line treatment; however, osimertinib did not have worse toxicities scores compared to other TKI treatments and had less severe skin rash compared to gefitinib ($P < .0013$). Skin rash however did not impact HUS under-scoring the need to carefully analyse the impact of toxicities in clinical studies. In addition, when comparing toxicities and symptoms with HUS, we identified mild-to-moderate inverse correlations between HUS and the majority of toxicity scores ($\rho = 0.16$ to $-0.56$), as well as ESAS ($\rho = -0.39$ to $-0.62$). This further supports the similarities in HUS incurred across TKI treatments when considering toxicity as an important partial driver of HUS. However, the absence of very strong correlations suggests that more than just one single symptom or driver impacts HUS.

Furthermore, we identified important differences in common symptom and toxicity questionnaires which may impact HUS: for example, ESAS scores of anxiety, depression, and well-being ($\rho > 0.5$) are not captured by the patient-reported toxicity questionnaire used, but are captured to some degree
within EQ5D, supporting slightly stronger correlations between ESAS and HUS. Another explanation for stronger correlations between ESAS symptoms and HUS may be that the inclusion of these generic symptoms applies to all patients as opposed to specific toxicities similar to PRO-CTCAE. Thus, a deeper understanding of patient-reported outcome data, especially how it impacts HUS, is still required and should be captured within clinical trials.

We verified the correlation between HUS and relevant clinico-demographic factors such as age, ECOG performance score, metastatic burden, disease state, and treatment group in the real world.26,27 Particularly, in this EGFRm enriched population, we did not find that the presence of brain metastases had a significant impact on HUS, despite brain involvement and their associated treatments being commonly regarded as a significant cause of morbidity.40 This supports a recent article, which demonstrated an effect on HUS by mutational subtype, prior radiation and disease control rather than presence of brain metastases.41 While bone metastases appeared to significantly affect HUS on UVA, they were not found to contribute overall to HUS in our MVA. This challenges the potential impact of bone metastases on HRQoL, such as previous report of bone as a particularly challenging site for pain control and treatment,42 further the need for real-world HUS. Given the correlation between HUS to clinically relevant factors and symptoms reported in EGFRm patients, our study demonstrates that the HUS generated by EQ-5D are clinically appropriate to use for economic analyses in this subpopulation of advanced lung cancer and should be included in cost-effectiveness studies.

There are several limitations to our study. As our study population consisted of cancer outpatients, there may be a recruitment bias towards fitter (ie nonhospital) patients who were able to attend clinic, with sicker patients declining to participate. Furthermore, as one patient was able to contribute multiple encounters, those who felt better and attended more clinics could contribute more data points. Our study assessed patients within a single specialized cancer care center, which may limit the generalizability of our findings to geographic regions that have very different resources and clinical practices. Similarly, given the numerous treatment options offered at our center, the patient population may include more individuals with higher disease burden and on subsequent lines of treatment compared to other centers. This is reflected in the baseline demographic characteristics of our study population. To mitigate this, we limited our analysis to focus on gefitinib, osimertinib, and chemotherapy as major treatment groups. This heterogeneity in the patient population studied is also a limitation when comparing toxicity and symptoms across line of therapy. However, we conducted a sensitivity analysis of specific line to line treatment, which demonstrated similar results as reported, and a MVA examining the effect of clinico-demographic factors on toxicity score did not show significant association between treatment line and toxicity severity. Furthermore the similar profiles between osimertinib and gefitinib despite the use of osimertinib predominantly in second line would support the more favourable side effect profile of osimertinib from the FLAURA study,14 given its use in treatment naïve patients.

5 | CONCLUSION

In a real-world Canadian EGFRm-NSCLC population, we found that first-line gefitinib and third-generation osimertinib had similar mean HUS and patient-reported toxicity and symptom scores. All TKI treatments had higher mean HUS compared to chemotherapy which was durable over time and was minimally disturbed by disease progression. Patient-reported toxicities and symptoms correlated with lower HUS across all treatment groups, demonstrating the importance of tempering toxicities to improve HUS. Our analyses also support the application of EQ-5D in the real world setting as a robust means for generating HUS in the EGFRm population. As EGFR-targeted treatment continues to expand, more real-world studies are needed to assess corresponding toxicities and impact on HUS to facilitate reliable cost-effectiveness analyses for new and existing treatments.

ACKNOWLEDGMENTS

This research was supported by the Alan Brown Chair in Molecular Genomics, Posluns Family Fund, Lusi Wong Early Detection of Lung Cancer Program, the Division of Medical Oncology at the University of Toronto, a Canadian Cancer Society Research Institute Impact Grant, and an unrestricted grant from AstraZeneca Canada. None of the aforementioned agencies were involved in design of the study and collection, analysis, and interpretation of the data; with the exception of AstraZeneca, which was involved in manuscript review.
DATA AVAILABILITY STATEMENT

All datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

ORCID

Shirley Xue Jiang https://orcid.org/0000-0003-0164-0619

REFERENCES

1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892-2911.

2. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998.

3. Ess SM, Herrmann C, Frick H, et al. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: a comprehensive evaluation of real world practices. Eur J Cancer Care (Engl). 2017;26(6):e12721.

4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388. http://dx.doi.org/10.1056/NEJMoai0909530

5. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2011;12(8):735-742.

6. Yang J-H, Wu Y-L, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-151.

7. Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244-2250.

8. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868-3874.

9. Kimura M, Yasue F, Usami E, et al. Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Mol Clin Oncol. 2018;9(2):201-206.

10. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011;17(6):1616-1622.

11. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-2247.

12. Mok TS, Wu Y-L, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629-640.

13. Goss G, Tsai C-M, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643-1652.

14. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113-125.

15. Ramalingam SS, Yang JC-H, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36;841-849.

16. Goss G, Tsai C-M, Shepherd FA, et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018;29(3):687-693.

17. Kuan F-C, Kuo L-T, Chen M-C, et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer. 2015;113(10):1519-1528.

18. Zhao D, Chen X, Qin NA, et al. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer. Sci Rep. 2017;7:40374.

19. Aguiar PN, Haaland B, Park W, San Tan P, Del Giglio A, de Lima LG. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer. JAMA Oncol. 2018;4(8):1080-1084.

20. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2016;18;18):330-3317.

21. Wu B, Gu X, Zhang Q, Xie F. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019:24-349-357.

22. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5-21.

23. Griesbach I, Palmer M, Fayers PM, Ellis S. Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib. BMJ Open. 2014;4(10):e005762.

24. Trippoli S, Vaiani M, Lucioni C, Messori A; Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics. 2001;19(8):855-863.

25. Tramontano AC, Schrag DL, Malin JK, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the cancer care outcomes research and surveillance (CanCORS) study. Med Decis Making. 2015;35(3):371-387.

26. Doyle S, Lloyd A, Walker M. Health state utility scores in advanced small cell lung cancers: a systematic review and meta-analysis. Pharmacoeconomics. 2001;19(8):855-863.

27. Labbé C, Leung Y, Silva Lemes JG, et al. Real-world EQ5D health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2015;84(1):151-152.

28. Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res. 2003;114(1):1-5.

29. Yang S-C, Lin C-C, Lai W-W, et al. Dynamic changes in quality of life after three first-line therapies for EGFR
mutation-positive advanced non-small-cell lung cancer. Ther Adv Med Oncol. 2018;10:PMID:28027077.
30. Park K, Tan E-H, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577-589.
31. Bansback N, Tsujiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS ONE. 2012;7(2):e31115.
32. Korpanty GI, Kamel-Reid S, Pintilie M, et al. Lung cancer in never smokers from the Princess Margaret Cancer Centre. Oncotarget. 2018;9(32):22559-22570.
33. Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.
34. Bagha SM, Macedo A, Jacks LM, et al. The utility of the Edmonton Symptom Assessment System in screening for anxiety and depression. Eur J Cancer Care (Engl). 2012;21(1):60-69.
35. Bodnar C, Ryan J, Green M. Health state utility measured by EQ-5D-5L for EGFRm T790M NSCLC patients treated with osimertinib. Ann Oncol. 2016;27(suppl_6). https://doi.org/10.1093/annonc/mdw377.21
36. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5(1):365.
37. Tudor RA, D’Silva A, Tremblay A, et al. Beyond disease-progression: clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. PLoS ONE. 2017;12(8):e0181867.
38. Ding PN, Lord SJ, Gebski V, Links M, Thoracic V. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):633-643.
39. Ishikawa A, Ohara G, Nakazawa K, et al. Chemotherapy-induced complications in patients with lung cancer: an evaluation by pharmacists. Mol Clin Oncol. 2013;1(1):65-68.
40. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small cell lung cancer. Cancer Treat Rev. 2016;45:139-162.
41. O’Kane GM, Su J, Tse BC, et al. The impact of brain metastases and associated neurocognitive aspects on health utility scores in EGFR mutated and ALK rearranged NSCLC: a real world evidence analysis. Oncologist. 2019;24:e501-e509.
42. Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer. 2010;67(1):4-11.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Jiang SX, Walton RN, Hueniken K, et al. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. Cancer Med. 2019;8:7542–7555. https://doi.org/10.1002/cam4.2603